sulfasalazine has been researched along with Anemia, Sickle Cell in 3 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Anemia, Sickle Cell: A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaul, DK | 1 |
| Liu, XD | 1 |
| Choong, S | 1 |
| Belcher, JD | 1 |
| Vercellotti, GM | 1 |
| Hebbel, RP | 2 |
| Makis, AC | 1 |
| Hatzimichael, EC | 1 |
| Stebbing, J | 1 |
| Solovey, AA | 1 |
| Solovey, AN | 1 |
| Harkness, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of Simvastatin (Zocor) Therapy in Sickle Cell Disease[NCT00508027] | Phase 1/Phase 2 | 42 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in plasma hemoglobin (Hb) level after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days
| Intervention | gm/dL (Mean) |
|---|---|
| Simvastatin, Dose Level 1 | -0.2 |
| Simvastatin, Dose Level 2 | 0.1 |
| Simvastatin, Dose Level 3 | -0.4 |
Change in plasma high sensitivity C-reactive protein levels in subjects treated with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days
| Intervention | mg/L (Mean) |
|---|---|
| Simvastatin, Dose Level 1 | -7.7 |
| Simvastatin, Dose Level 2 | -3.6 |
Change in plasma IL-6 level after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days
| Intervention | pg/mL (Mean) |
|---|---|
| Simvastatin, Dose Level 1 | -0.6 |
| Simvastatin, Dose Level 2 | -0.3 |
Measurements of the levels of plasma nitric oxide metabolites (NOx), high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), vascular cell adhesion molecule-1 (VCAM-1), tissue factor (TF) and vascular endothelial growth factor (VEGF)were performed before and after simvastatin treatment. Changes in mean plasma biomarker levels were assessed for each dose level; however, dose level 3 results were not analyzed, as only 2 subjects were enrolled in this dose group. (NCT00508027)
Timeframe: Baseline, 21 days
| Intervention | micromolar (Mean) |
|---|---|
| Simvastatin, Dose Level 1 | 7 |
| Simvastatin, Dose Level 2 | 19.7 |
Change in plasma tissue factor (TF) levels after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days
| Intervention | pg/mL (Mean) |
|---|---|
| Simvastatin, Dose Level 1 | -9 |
| Simvastatin, Dose Level 2 | -36 |
Change in plasma vascular cellular adhesion molecule-1 levels after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days
| Intervention | ng/mL (Mean) |
|---|---|
| Simvastatin, Dose Level 1 | -44 |
| Simvastatin, Dose Level 2 | -86 |
Change in plasma vascular endothelial adhesion molecule-1 levels after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days
| Intervention | pg/mL (Mean) |
|---|---|
| Dose Level 1 | -164 |
| Dose Level 2 | -30 |
Change in serum alanine transaminase (ALT) after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days
| Intervention | U/L (Mean) |
|---|---|
| Simvastatin, Dose Level 1 | 4 |
| Simvastatin, Dose Level 2 | 3 |
| Simvastatin, Dose Level 3 | -3 |
Change in serum creatine kinase (CK) levels after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days
| Intervention | U/L (Mean) |
|---|---|
| Simvastatin, Dose Level 1 | 57 |
| Simvastatin, Dose Level 2 | 20 |
| Simvastatin, Dose Level 3 | 62 |
Change in serum creatinine (Cr) levels after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days
| Intervention | mg/dL (Mean) |
|---|---|
| Simvastatin, Dose Level 1 | 0.03 |
| Simvastatin, Dose Level 2 | 0.04 |
| Simvastatin, Dose Level 3 | -0.1 |
Change in serum total cholesterol level after treatment with simvastatin (NCT00508027)
Timeframe: Baseline, 21 days
| Intervention | mg/dL (Mean) |
|---|---|
| Simvastatin, Dose Level 1 | -16 |
| Simvastatin, Dose Level 2 | -18 |
| Simvastatin, Dose Level 3 | -18 |
1 review available for sulfasalazine and Anemia, Sickle Cell
| Article | Year |
|---|---|
The genomics of new drugs in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Azacitidine; Butyrates; Decitabine; Drug Resistance; Human | 2006 |
2 other studies available for sulfasalazine and Anemia, Sickle Cell
| Article | Year |
|---|---|
Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice.
Topics: Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Constriction, | 2004 |
Modulation of endothelial cell activation in sickle cell disease: a pilot study.
Topics: Adult; Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents, Non-Steroidal; Drug Evaluation; E-Sel | 2001 |